A poster titled Updated data from ABOYA-119: A phase 1/2a trial of ATRN-119, a novel macrocyclic ATR inhibitor, in patients with advanced solid tumors harboring DNA damage will be presented at the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback